CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.35 CNY | +0.13% |
|
-0.58% | +21.20% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +21.20% | 2.83B | D- | ||
| +40.73% | 734B | C+ | ||
| +32.83% | 591B | B | ||
| -6.30% | 350B | C+ | ||
| +15.15% | 315B | B- | ||
| +4.05% | 276B | C+ | ||
| +15.00% | 238B | B+ | ||
| +9.78% | 206B | B- | ||
| -5.52% | 204B | A+ | ||
| +6.17% | 161B | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 002773 Stock
- Ratings Chengdu Kanghong Pharmaceutical Group Co., Ltd
